Top Story Today
Astellas Drops $1.7B on a Cancer Drug That Only Wakes Up When It Finds a Tumor
Astellas is paying up to $1.7 billion for VIR-5500, a "masked" T-cell engager that stays completely inert in the bloodstream and only activates when tumor enzymes strip off its molecular safety pins. In a Phase 1 prostate cancer trial, 82% of patients at top doses saw their PSA levels cut in half, with only about 2% experiencing grade 3 or higher cytokine release syndrome. Earlier drugs in the same class were plagued by brutal toxicity (one program saw grade 3-4 events in 81% of patients). Vir gets $335 million upfront, with a 50/50 U.S. profit split and a potential Phase 3 launch in 2027.
Why it matters: The deal validates masked bispecific T-cell engagers as a high-value modality in solid tumors, where toxicity has historically killed more promising drugs than the diseases they targeted. If the safety profile holds, it could crack open a new treatment paradigm across multiple cancer types.
Read more →Clinical Setbacks
Sarepta's $2.5B Gene Therapy Strikes Out, Triggering 500 Layoffs and a Black Box Warning
Elevidys, the most closely watched gene therapy in rare disease, failed its Phase III confirmatory trial: treated boys improved just 0.65 points more than placebo on a motor function test (p=0.24). The FDA is adding a black box warning for liver injury after multiple patient deaths. Sarepta is cutting 36% of its workforce and pivoting toward its siRNA platform, raising hard questions about the accelerated approval pathway for gene and RNA therapies.
Read more →Deals & Strategy
GSK Assembles a Billion-Dollar Combo to Chase the First Functional Cure for Hepatitis B
GSK secured worldwide rights to J&J's siRNA drug JNJ-3989 for roughly $1 billion, planning to combine it with bepirovirsen, its own therapy that achieved functional cure in up to 26% of selected patients (versus 0% for placebo). With 240 million people infected and current treatments curing fewer than 5%, a Phase 2 combo trial is next. Approval decisions on bepirovirsen alone are expected by Q4 2026.
Read more →Novo Nordisk Pays Up to $327M for a Molecular GPS That Crosses the Blood-Brain Barrier
Novo licensed Vect-Horus's VECTrans platform, which uses engineered peptides to ferry drugs across the blood-brain barrier by hijacking natural receptor pathways. The deal covers three programs and fits a broader pharma arms race over targeted delivery, where Novartis, Roche, and others have collectively committed tens of billions to own the infrastructure that gets next-generation drugs where they need to go.
Read more →Public Health
Another OTC Naloxone Spray Hits Shelves as Overdose Deaths Keep Falling
The FDA approved Rextovy, a new over-the-counter naloxone nasal spray from Amphastar, joining Narcan and RiVive on pharmacy shelves with no prescription required. Each new entrant is helping push prices lower. U.S. overdose deaths have dropped roughly 29% from their peak, but nearly 70,000 people still died last year.
Read more →